Zobrazeno 1 - 10 of 101 pro vyhledávání: '"Frezza, Am"'
3
Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience
Autor: Vincenzi, B, Nannini, M, Fumagalli, E, Bronte, G, Frezza, Am, De Lisi, D, Spalato Ceruso, M, Santini, D, Badalamenti, G, Pantaleo, Ma, Russo, A, Dei Tos AP, Casali, P, Tonini, G
Publikováno v: Journal of Clinical Oncology. 32:10515-10515
10515 Background: Data from metastatic GIST patients harbouring exon 11 mutation who received a second line treatment with sunitinib or imatinib dose escalation were retrospectively analysed to compare survival. Methods: 123 exon 11 mutated advanced
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f17b61b281c10c4944b57f896744f90
https://doi.org/10.1200/jco.2014.32.15_suppl.10515
Zobrazit plný text záznamu
5
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
Autor: Michele Caraglia, Anna Maria Frezza, Raffaele Addeo, Francesco Giuliani, Salvatore Del Prete, Liliana Montella, Daniele Santini, Bruno Vincenzi, Giuseppe Colucci, Sergio Rizzo, Antonio Russo, Olga Venditti, Giuseppe Tonini
Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e20b064450b3b3658edb220d241c33
http://hdl.handle.net/10447/99249
Zobrazit plný text záznamu
8
Akademický článek
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression.
Autor: Stacchiotti S; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Martini S; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Pasquali S; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Frezza AM; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Beretta A; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Percio S; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Lecchi M; Unit of Bioinformatics and Biostatistics, Department Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tortoreto M; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Barisella M; Pathology Unit, ASST Fatebenefratelli Sacco, Milan, Italy., Collini P; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Dagrada GP; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Merlini A; Department of Oncology, University of Turin, Turin, Italy., Huang PH; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom., Jenks A; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom., Jones RL; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Tap WD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Ingrosso M; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Morosi C; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Brich S; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Giani C; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Verderio P; Unit of Bioinformatics and Biostatistics, Department Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Casali PG; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Leonard H; Chair of Trustees of the EHE Rare Cancer Charity UK, Charity Number 1162472, Kingston-Upon-Thames, United Kingdom., Gronchi A; Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Zuco V; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Zaffaroni N; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Nov 15; Vol. 30 (22), pp. 5122-5137.
Zobrazit plný text záznamu
9
Akademický článek
Proximal and Classic Epithelioid Sarcomas are Distinct Molecular Entities Defined by MYC/GATA3 and SOX17/Endothelial Markers, Respectively.
Autor: Sigalotti L; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Frezza AM; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sbaraglia M; Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy., Del Savio E; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Baldazzi D; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Valenti B; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Bellan E; Department of Pathology, Azienda Ospedale Università Padova, Padua, Italy., De Benedictis I; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Doni M; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Gambarotti M; Department of Pathology, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy., Vincenzi B; Department of Medical Oncology, Università Campus Biomedico di Roma, Rome, Italy., Brunello A; Department of Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV, IRCCS, Padua, Italy., Baldi GG; Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy., Palmerini E; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy., Pasquali S; Department of Applied Research and Technological Development, Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ciuffetti ME; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Varano V; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy., Cappello F; Department of Pathology, Azienda Ospedale Università Padova, Padua, Italy., Appolloni V; Italian Sarcoma Group, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pastrello C; Division of Orthopaedic Surgery, Schroeder Arthritis Institute, Toronto, Canada., Jurisica I; Division of Orthopaedic Surgery, Schroeder Arthritis Institute, Toronto, Canada; Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, Toronto, Canada; Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, Canada; Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia., Gronchi A; Department of Sarcoma Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Stacchiotti S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Casali PG; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., Dei Tos AP; Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy., Maestro R; Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy. Electronic address: rmaestro@cro.it.
Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2024 Nov 02; Vol. 38 (1), pp. 100647. Date of Electronic Publication: 2024 Nov 02.
Zobrazit plný text záznamu
10
Akademický článek
The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: The protocol of an international and collaborative effort on an ultra-rare entity.
Autor: Frezza AM; Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology 2, Milan, Italy., Leonard H; EHE Rare Cancer Charity, London, United Kingdom., Aggerholm-Pedersen N; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Badalamenti G; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy., Baili P; Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Tumori, Data Science Unit, Milan, Italy., Baldi GG; Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy., Bauer S; Medical Oncology, University Hospital Essen, Essen, Germany., Bazzurri S; Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy., Benzonelli I; Medical Oncology, Ospedale San Luigi, Orbassano, Italy., Bertuzzi A; Medical Oncology, IRCCS, Humanitas Research Hospital, Rozzano-Milano, Italy., Blay JY; Medical Oncology, Centre Léon Bérard, Lyon, France., Bianchi G; IRCCS Istituto Ortopedico Rizzoli, Clinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, Bologna, Italy., Bonfarnuzzo S; Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Tumori, Data Science Unit, Milan, Italy., Bouvier C; Medical Oncology, Centre Léon Bérard, Lyon, France., Boye K; Medical Oncology, Oslo University Hospital, Oslo, Norway., Martin Broto J; Medical Oncology, Fundación Jimenez Diaz University Hospital, Madrid, Spain., Brunello A; Istituto Oncologico Veneto IOV-IRCCS, Medical Oncology 1, Padua, Italy., Campanacci D; Orthopaedic Oncology, Careggi University Hospital, Florence, Italy., Casali PG; Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology 2, Milan, Italy., Cicala C; Medical Oncology, Hospital Universitari Vall d'Hebron, Spain., Crotti E; Medical Oncology, IRCCS, Humanitas Research Hospital, Rozzano-Milano, Italy., D'Ambrosio L; Medical Oncology, Ospedale San Luigi, Orbassano, Italy., Dei Tos AP; Department of Pathology, Azienda Ospedaliera di Padova, Padua, Italy., Dieckmann N; Medical Oncology, University Hospital Essen, Essen, Germany., Dufresne A; Medical Oncology, Centre Léon Bérard, Lyon, France., Elston S; Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Ferraresi V; Sarcomas and Rare Tumors Departmental Unit-IRCCS Regina Elena National Cancer Institute, Rome, Italy., Gabellini S; Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy., Giani C; Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology 2, Milan, Italy., Giannusa V; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy., Gil Sanjines M; Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Tumori, Evaluative Epidemiology Unit, Milan, Italy., Grassani T; Medical Oncology, Università Campus Bio-Medico, Rome, Italy., Gronchi A; Fondazione IRCCS Istituto Nazionale Tumori, Sarcoma Surgery, Milan, Italy., Lasalvia P; Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Tumori, Evaluative Epidemiology Unit, Milan, Italy., Lindskog S; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Hindi N; Medical Oncology, Fundación Jimenez Diaz University Hospital, Madrid, Spain., Ingrosso M; Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology 2, Milan, Italy., Ivanescu A; EHE Italia, Milan, Italy., Jones R; Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Lugowska I; Maria Skłodowska Curie Institute-Oncology Centre, Early Phase Trial Unit, Warsaw, Poland., Ketzer J; Medical Oncology, University Hospital Essen, Essen, Germany., Mariuk-Jarema A; Maria Skłodowska Curie Institute-Oncology Centre, Early Phase Trial Unit, Warsaw, Poland., Mazzocca A; Medical Oncology, Università Campus Bio-Medico, Rome, Italy., Monteleone L; Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology 2, Milan, Italy., Morosi C; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Napolitano A; Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Nardozza F; IRCCS Regina Elena National Cancer Institute, UOSD Clinical Trial Center, Biostatistics and Bioinformatics, Rome, Italy., Neri E; Orthopaedic Oncology, Careggi University Hospital, Florence, Italy., Nilsson M; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Papakonstantinou A; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Breast Cancer, Endocrine Tumors and Sarcoma, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden., Pasquali S; Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Molecular Pharmacology Unit, Milan, Italy., Sbaraglia M; Department of Pathology, Azienda Ospedaliera di Padova, Padua, Italy., Scolari F; Orthopaedic Oncology, Careggi University Hospital, Florence, Italy., Szkandera J; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria., Valverde C; Medical Oncology, Hospital Universitari Vall d'Hebron, Spain., Vincenzi B; Medical Oncology, Università Campus Bio-Medico, Rome, Italy., Vizzaccaro S; Istituto Oncologico Veneto IOV-IRCCS, Medical Oncology 1, Padua, Italy., Zuccheri F; IRCCS Istituto Ortopedico Rizzoli, Clinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, Bologna, Italy., Stacchiotti S; Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology 2, Milan, Italy., Trama A; Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Tumori, Evaluative Epidemiology Unit, Milan, Italy.
Publikováno v: PloS one [PLoS One] 2024 Aug 12; Vol. 19 (8), pp. e0308387. Date of Electronic Publication: 2024 Aug 12 (Print Publication: 2024).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje